Pricing Sign in

JSPR

Jasper Therapeutics, Inc.distress 3/10 · well-funded / low risk

$0.76+2%today-78% from 52w high

jaspertx.com22 employeesFounded 2018Redwood City, CABiotechnology

Respiratory 1

Lead: chronic spontaneous urticaria · target c-Kit

Revenue

pre-revenue

Liquidity

$118M

Runway

1.7 yrs

Shares 1y

+72%

Price & events

-51.6% over 6M

CatalystRating changeDilutionFinancingdashed = today

+2.0%

1D

-1.8%

1W

+55.4%

1M

-16.0%

3M

-51.6%

6M

-76.8%

1Y

-96.5%

2Y

-99.2%

5Y

-99.3%

All

Overview

Market Cap: $21.27M
Volume: 102.66K
52 Week Range: $0.34 – $3.51
Total Shares: 28.00M
Float Shares: 23.31M
Short %: 6.22%
% Held by Insiders: 1.19%
% Held by Institutions: 56.57%
RVOL: 0.04x
Beta: 3.07

Pipeline stages · 2 programs

Briquilimab

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2026-08-13

Humanized anti-CD117 Monoclonal Antibody (JSP191)

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

Pipeline · 5 trials · 2 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2026-08-13 Estimated 50% readout ~2026-09-27 final ~2027-02-28	Phase 2	Briquilimab	Urticaria Chronic	67	active not recruiting
2026-10-31 Estimated 50% readout ~2026-12-15	Phase 1/2	Briquilimab	Chronic Spontaneous Urticaria	—	active not recruiting
2025-08-11	Phase 1	Briquilimab	Allergic Asthma	17	terminated
2025-07-31	Phase 1/2	Briquilimab	Chronic Inducible Urticaria	27	terminated
2025-07-07	Phase 1/2	Humanized anti-CD117 Monoclonal Antibody (JSP191)	SCID	23	terminated

Catalyst news & presentations · 13

second quarter of 2027readoutPhase 2KP-104 · Updated data from Stage 1 of Phase 2 basket trial in rare renal indicationsSEC 8-K
fourth quarter of 2026readoutPhase 2KP-104 · Interim data from Stage 1 of Phase 2 basket trial in rare renal indicationsSEC 8-K
second half of 2026Guided 55%trial initiationsecondaryPhase 2briquilimab · Phase 2b study of briquilimab in CSU expected to commence.SEC 8-K
2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
2026-07-16partnershipKP-301, KP-402 · Out-licensed to Mirador Therapeutics for $12M upfront and potential milestonesSEC 8-K
mid-2026trial initiationsecondaryPhase 2briquilimab · Commencement of Phase 2b studySEC 8-K
January 8, 2026 at 8:00am ETconferencedata presentationsecondarybriquilimab · Present updated data from BEACON study and open-label extensionSEC 8-K
second half of 2025trial initiationsecondaryPhase 2briquilimab · Registrational Phase 2b study expected to commenceSEC 8-K
4Q 2025readoutPhase 1/2briquilimab · Data from additional 10-12 patients in confounded BEACON cohortsSEC 8-K
2025-07-08trial discontinuedbriquilimab · Halting ongoing investigator-sponsored studiesSEC 8-K
July 7, 2025 at 8:30 a.m. EDTconferencedata presentationsecondarybriquilimab · Conference call and webinar to present updated BEACON Phase 1b/2a dataSEC 8-K
first half of 2025conferencedata presentationsecondaryPhase 1/2briquilimab · Full data from SPOTLIGHT study including 180mg cohort.SEC 8-K
week of January 6th, 2025readoutPhase 1/2briquilimab · Initial data from BEACON study including 180mg Q8W cohort.SEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 27,996,819 · 0 offerings/1y · 0 PIPEs

none

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Wall St ratings

buy · target $9 (+1106% upside) · 3 analysts

2026-05-15RBC CapitalSector Perform
2026-05-15TD CowenBuy → Hold
2026-04-01Evercore ISI GroupOutperform
2025-11-11RBC CapitalSector Perform
2025-09-22Evercore ISI GroupOutperform
2025-09-22JMP SecuritiesMarket Outperform

Competitors — c-Kit

CLDXCelldex Therapeutics, Inc.$2.7B · D3

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.